PubMed Health⌕ Search

Biomedical subjects

L Fabbri

Publications and source records attributed to L Fabbri.

At least 37 records · Page 2Linked to original sources
PubMed1982

Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy.

The effects of long-term treatment with 25-hydroxycholecalciferol (25OHD3) and disodium ethane-1-hydroxydiphosphonate, or 25OHD3 alone on biochemical parameters, and radiographic and quantitative histomorphometry of bone tissue were evaluated in 17 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and defective mineralization of varying degree and predominance. 100 micrograms/day of 25OHD3 significantly improved the state of bone mineralization in many patients with a pronounced fall in the osteoid volume and surface and produced a small reduction in the active resorption surface. Serum parathyroid hormone (iPTH) and alkaline phosphatase levels decreased in some patients. The combination of 25OHD3 with EHDP caused the healing of bone mineralization as did 25OHD3 alone and produced a significant fall in serum alkaline phosphatase and iPTH. The mean magnitude of the reduction in iPTH was higher in patients treated with 25OHD3 and EHDP than with 25OHD3 alone. Treatment with 25OHD3 and EHDP seems more effective for the improvement of osteitis fibrosa than is 25OHD3 alone.

Adult↗
PubMed1981

[Septic osteo-arthritis in hemodialyzed patients: an incident not to underestimate (author's transl)].

Three cases of septic osteo-arthritis were seen occuring in patients on dialysis treatment. The sites of involvement included lumbar spine, knee joint, ribs and wrist. The culture of the same microorganisms simultaneously from the arterovenous prothesis, blood and synovial fluid supports the hypothesis that the osteo-arthritis was the result of hematogenous spread of bacteria from the infected focus. Early diagnosis and treatment may prevent severe bone and joint damage.

Adult↗
PubMed1979

[Incidence and evolution of soft tissues calcifications in patients in periodic hemodialysis (author's transl)].

In a series of 92 patients' in hemodialysis the evolution of periarticular and vascular calcifications has been studied. A correlation exists between the incidence of arterial calcifications and the patients' age, while no direct correlation has been proved to exist with the duration of dialysis. In fact their annual average increase (8.4%) is similar to that of periarticular calcifications (12.2%).

Adolescent↗
PubMed1978

Treatment of ectopic calcification in uremia.

Nine uremic patients on maintenance hemodialysis who showed wide arterial and/or stable periarticular calcifications in spite of a well controlled hyperphosphatemia were treated with the diphosphonate disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) in doses of 7.5 to 10 mg/kg of body wt/per day for 5 to 9 months. No clinical or biochemical side-effects were noted. A significant reduction of the extent of periarticular calcifications was observed in five patients: two of them had a complete regression of soft-tissue calcifications, and one patient showed a reduction of arterial calcification. EHDP (7.5 to 10 mg/kg of body wt/per day) induced a significant increase of the osteoid volume and osteoid surface without significant modification of the calcification front. No evident effect on bone resorption and on the mineral content of the radius has been observed.

Adult↗
PubMed1977

[Chronic broncopneumopathy and pneumoconiosis in workers employed in phosphoric acid production (author's transl)].

Thirty-five subjects employed in a phosphoric acid producing plant were studied by the authors. The investigation included: history, according to the C.E.C.A. questionnaire for chronic bronchitis and emphysema; physical examination, chest X-ray spirometry and lung diffusing capacity for carbon monoxide by the steady state method (DLCOSS). High prevalence of chronic bronchitis (45.7%), obstructive spirometric impairment (37.1%), and decreased values of DlcoSS (31.4%) were detected. Two subjects were found to be affected with p 1/0 and 7 with p 0/1 pneumoconiosis. Such findings were significantly related to the lenght of working activity as well as to dust and gaseous fluoride (hydrofluoric acid, hexafluorosilicic acid and silicon tetrafluoride) exposure.

Adult↗
PubMed1976

[Epidemiologic evaluation of isocyanate immediate irritative action: 'one day effect' control (author's transl)].

Nineteen MDI exposed workers showed ventilatory changes, after eight hour exposure, mainly involving upper respiratory airways; the changes reversed following a bronchodilator aerosol. An incomplete recovery of VC was found in some subjects; therefore, the possibility of changes in the lung elastic recoil forces was hypothesized. No statistically significant differences were found as to occupation and smoking habit, which suggests that even low MDI concentrations could be enough to give rise to acute effects. The greater impairment found in subjects who were already affected by morning time emphasizes the necessity that such subjects were not employed in their specific work.

Adult↗
PubMed1975

[Periaticular metastatic calcifications in uremic patients].

Metastatic periarticular calcification was observed in 18 per cent of a series of 61 patients receiving haemodialytic treatment for from 3 months to over 5 yr. Calcium deposits occurred more frequently in the 1st and 2nd yr of treatment. The factors responsible included the plasma calcium-phosphorus product, non-optimal calcium and magnesium ion concentration in the dialysis bath, and secondary hyperparathyroidism. Tests for the diagnosis of parathyroid hyperfunction in the uraemic subject are described. The therapeutic criteria adopted in the prevention and management of calcification are also discussed.

Acidosis↗
PubMedDate not supplied

High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group.

This multicentre, double-blind study compared (100 mg) sumatriptan administered orally with placebo in treating an acute attack of migraine; 238 patients were studied over a 48-h period. Four hours after treatment, 92 of the 142 evaluable sumatriptan patients (65%) showed significant reductions (P < 0.001) in headache severity, clinical disability and accompanying symptoms compared with 32 of the 80 evaluable placebo-treated patients (40%). The duration of attack prior to taking medication and the history of persistent migraine do not influence the observed difference between the two treatment regimens (sumatriptan and placebo), which remained statistically significant (P < 0.001) in both cases. The incidence of headache recurrence in patients who experienced relief 4 h after initial treatment was low, occurring in 16 (17%) and 4 (13%) of the sumatriptan- and placebo-treated patients, respectively. Only patients with a history of migraine attacks lasting longer than 24 h suffered headache recurrences, and these recurrences were not consistent with the International Headache Society definition of migraine. Treatment with sumatriptan was well tolerated.

Acute Disease↗